Sarcopenia
Conditions
Brief summary
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.
Detailed description
GLP-1 receptor agonists are highly effective for weight loss and increasing in popularity for those trying to lose weight. One concern with these medications is the potential for loss of lean tissue mass during rapid weight loss. This may affect strength and functional performance in people taking these medications. Resistance-training helps to offset loss of muscle mass during weight loss. Supplementation with creatine monohydrate is also effective for improving muscle mass and strength. The purpose of this pilot study is to determine the effectiveness of creatine supplementation during a resistance training program in people who are starting GLP-receptor agonist medication for preventing loss of lean tissue mass and functional performance. The investigators will randomize 40 people who are starting GLP-1 agonists to receive either 10g per day creatine or placebo during a resistance-training program (i.e., resistance-training three days per week for 12 weeks). It is hypothesized that participants on the creatine supplement will have superior maintenance of lean tissue mass and function performance compared to participants taking placebo.
Interventions
DIETARY_SUPPLEMENTDietary supplementation during a 12 week resistance-training program (creatine)
creatine supplementation
DIETARY_SUPPLEMENTDietary supplementation during a 12 week resistance-training program (placebo)
Placebo
Sponsors
University of Saskatchewan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Starting GLP-1 agonist therapy * 18 years of age or older
Exclusion criteria
* Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in sit to stand performance (number of times) | 12 weeks | change in number of times sitting and standing in 30 seconds |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in 10 meter gait speed (m/s) | 12 weeks | change in walking speed over 10 meters |
| Change in timed up and go (m/s) | 12 weeks | change in time to stand up, walk 3m, turn, around, walk 3 m and sit down |
| Change in lean tissue mass (kg) | 12 weeks | Change in lean tissue mass as determined by dual energy x-ray absorptiometry |
| Change in fat mass (kg) | 12 weeks | Change in fat mass as determined by dual energy x-ray absorptiometry |
| Change in whole body bone mineral density (g/cm squared) | 12 weeks | Change in bone mineral density as determined by dual energy x-ray absorptiometry |
| Change in femoral neck bone mineral density (g/cm squared) | 12 weeks | Change in bone mineral density as determined by dual energy x-ray absorptiometry |
| Change in total hip bone mineral density (g/cm squared) | 12 weeks | Change in bone mineral density as determined by dual energy x-ray absorptiometry |
| Change in lumbar spine bone mineral density (g/cm squared) | 12 weeks | Change in bone mineral density as determined by dual energy x-ray absorptiometry |
| Change in hip section modulus (cm-cubed) | 12 weeks | Change in hip section modulus as determined by dual energy x-ray absorptiometry |
| Change in muscle thickness of the biceps (cm) | 12 weeks | Change in muscle thickness measured by ultrasound |
| Change in muscle thickness of the quadriceps (cm) | 12 weeks | Change in muscle thickness measured by ultrasound |
| Change in bench press strength (kg) | 12 weeks | change in upper body strength measured by predicted one repetition maximum |
| Change in leg extension strength (kg) | 12 weeks | Change in lower body strength measured by predicted one repetition maximum |
| Change in hip buckling ratio (ratio) | 12 weeks | Change in hip buckling ratio as determined by dual energy x-ray absorptiometry |
| Change in hip cross-sectional area (cm-squared) | 12 weeks | Change in hip cross-sectional area as determined by dual energy x-ray absorptiometry |
| Change in hip cortical thickness (cm) | 12 weeks | Change in hip cortical thickness as determined by dual energy x-ray absorptiometry |
Countries
Canada
Contacts
CONTACTPhilip D Chilibeck, PhD
PRINCIPAL_INVESTIGATORPhilip Chilibeck, PhD
University of Saskatchewan
Outcome results
None listed